Nina Rosa de Castro Musolino

Author

Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo ORCID

Also Known As

Musolino, Nina R. De C., Musolino, Nina Rosa, N. Musolino, NINA ROSA MUSOLINO, Nina Musolino, Nina R de Castro Musolino, Nina R. C. Musolino, Nina R. Musolino, Nina R. de C. Musolino, Nina R. de Castro Musolino

Publications

1.5K

Citations

H-Index

Concepts

All Affiliations

Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo Universidade de São Paulo Hospital Universitário Clementino Fraga Filho Universidade Federal do Rio de Janeiro Hospital das Clínicas da Universidade Federal de Pernambuco

About

Nina Rosa de Castro Musolino is an author at Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo specializing in medicine, pathology, and pharmacotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	6	6	254
2	Endocrinology	2	2	105
3	Health Sciences	1	1	35
4	Allergy	1	1	77
5	Immunology	1	1	77

Nina Rosa de Castro Musolino

Publications

925

Citations

H-Index

Page 1

	Year	Citations
Landscape of Familial Isolated and Young-Onset Pituitary Adenomas: Prospective Diagnosis in<i>AIP</i>Mutation Carriers Laura C. Hernández‐Ramírez, Plamena Gabrovska, Judit Dénes, The Journal of Clinical Endocrinology & Metabolism	2015	167
Treatment of acromegaly with octreotide‐LAR: extensive experience in a Brazilian institution Raquel S. Jallad, Nina Rosa de Castro Musolino, L R Salgado, Clinical Endocrinology	2005	87
Acromegaly: correlation between expression of somatostatin receptor subtypes and response to octreotide-lar treatment A Casarini, Raquel S. Jallad, Emília M. Pinto, Pituitary Octreotide-lar TreatmentAllergySomatostatin Receptor SubtypesHormonal ReceptorImmunology	2009	77
Impact of recombinant human growth hormone (rh-GH) treatment on psychiatric, neuropsychological and clinical profiles of GH deficient adults: a placebo - controlled trial Claudio Soares, Nina Rosa de Castro Musolino, MALEBRANCHE CUNHA NETO, Arquivos de Neuro-Psiquiatria	1999	72
Does partial surgical tumour removal influence the response to octreotide‐LAR in acromegalic patients previously resistant to the somatostatin analogue? Raquel S. Jallad, Nina Rosa de Castro Musolino, Sérgio Keidi Kodaira, Clinical Endocrinology	2007	65
Significant Benefits of <i>AIP</i> Testing and Clinical Screening in Familial Isolated and Young-onset Pituitary Tumors Pedro Marques, Francisca Caimari, Laura C. Hernández‐Ramírez, The Journal of Clinical Endocrinology & Metabolism	2020	64
Cabergoline in the Management of Residual Nonfunctioning Pituitary Adenoma Rafael Loch Batista, Nina Rosa de Castro Musolino, Valter Ângelo Sperling Cescato, American Journal of Clinical Oncology	2018	62
Pharmacokinetic profile of lanreotide Autogel<sup>®</sup> in patients with acromegaly after four deep subcutaneous injections of 60, 90 or 120 mg every 28 days Marcello D. Bronstein, Nina Rosa de Castro Musolino, Raquel S. Jallad, Clinical Endocrinology Therapeutic Drug MonitoringTranslational MedicineSubcutaneous InjectionsPharmacokinetic ProfileProlonged Release	2005	54
Treatment of acromegaly: is there still a place for radiotherapy? Raquel S. Jallad, Nina Rosa de Castro Musolino, L R Salgado, Pituitary MedicineRadiation OncologyTreatment OptionRadiation Therapy	2007	49
Machine Learning-based Prediction Model for Treatment of Acromegaly With First-generation Somatostatin Receptor Ligands Luiz Eduardo Wildemberg, Aline Helen da Silva Camacho, Renan Lyra Miranda, The Journal of Clinical Endocrinology & Metabolism	2021	47

Page 1